VolitionRx Limited (VNRX) - 10-K Filing Summary
Business Context and Reporting Period
Company: VolitionRx Limited (VNRX)
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: VolitionRx is a multi-national epigenetics company developing blood tests for early detection and monitoring of diseases, including cancer and sepsis (NETosis). Key product pillars include Nu.Q Vet (veterinary cancer screening), Nu.Q NETs (sepsis detection), Nu.Q Cancer (human cancer screening), and Capture-Seq/PCR technologies. The company operates facilities in Belgium, the UK, the US, and Singapore.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1.73 million | $1.23 million |
| Net Loss | $(23.50) million | $(27.26) million |
| Operating Expenses | $23.47 million | $28.26 million |
| Cash and Cash Equivalents | $1.12 million | $3.26 million |
| Accumulated Deficit | $(252.90) million | $(229.54) million |
| Outstanding Shares | 125.78 million | 96.10 million |
Note: The filing text does not provide specific gross margin percentages or EBITDA figures.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 40% year-over-year, driven by a 98% increase in service revenue and a 27% increase in product revenue. Product sales are primarily from the Nu.Q Vet Cancer Test and Nu.Q Discover kits.
- Expense Reduction: Total operating expenses decreased 17% to $23.5 million. Research and Development (R&D) expenses dropped 30% to $10.1 million due to reduced clinical trial activity and personnel costs. Sales and marketing expenses fell 27% to $3.9 million.
- Debt Financing: The company issued a $7.5 million senior secured convertible note to Lind Global Asset Management in May 2025. This resulted in significant non-cash interest expense ($1.96 million amortization of debt discount) and the recognition of a derivative liability.
- Equity Dilution: The company raised approximately $17.1 million in net proceeds from financing activities in 2025 through various registered direct offerings, private placements, and an underwritten public offering, increasing outstanding shares by roughly 30%.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company's independent auditors have issued a "going concern" opinion, expressing substantial doubt about the company's ability to continue operations without additional financing. Management plans to address this through further equity/debt financing, licensing deals, and cost controls.
- Commercialization Milestones:
- Nu.Q Vet: First revenue from the CE-marked Nu.Q NETs automated product was recorded in Q1 2025. A potential $5 million milestone payment is anticipated upon publication of a peer-reviewed paper regarding feline lymphoma detection.
- Nu.Q Cancer: Received first order for clinical certification in Q4 2025. Reimbursement submission preparation is underway in France, with routine clinical use anticipated by Q4 2026.
- Listing Compliance: The company received a notice of non-compliance from NYSE American regarding listing standards (stock price, market cap, etc.) on February 6, 2026. A compliance plan has been submitted with a target date of August 6, 2027.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding insufficient written documentation of policies and procedures. Remediation efforts are ongoing.
- Debt Covenants: The Lind Notes contain restrictive covenants and conversion features that could result in significant dilution or acceleration of debt in the event of a default.
Investor Verification Checklist
- Liquidity Runway: Verify current cash burn rate against the $1.12 million cash balance to assess immediate risk of insolvency.
- Debt Conversion Terms: Review the specific conversion prices and default triggers for the $7.5 million Lind Note and the subsequent $2.4 million 2026 Lind Note to understand potential dilution scenarios.
- Revenue Recognition: Confirm the timing and certainty of the $5 million feline lymphoma milestone payment and the $22.3 million deferred revenue recognition schedule from the Heska agreement.
- Listing Status: Monitor the company's progress on the NYSE American compliance plan to avoid delisting.
- Internal Control Remediation: Track the implementation of new accounting policies and the hiring of internal control consultants to address material weaknesses.